J&J scores ap­proval for Ry­bre­vant com­bo in first-line lung can­cer, stok­ing ri­val­ry with Tagris­so

John­son & John­son scored a la­bel ex­pan­sion for Ry­bre­vant in com­bi­na­tion with the new­ly-ap­proved Laz­cluze to treat cer­tain first-line lung can­cer pa­tients, putting it in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER